Immunodeficient patient experience of emergency switch from intravenous to rapid push subcutaneous immunoglobulin replacement therapy during coronavirus disease 2019 shieldingArticle Published on 2022-12-012022-11-15 Journal: Current opinion in allergy and clinical immunology [Category] 진단, [키워드] administration Anxiety assessment collected Concentration coronavirus disease COVID-19 greater high risk IgG IgG level immunodeficient patient Immunoglobulin immunoglobulin replacement therapy In-hospital Infection intravenous Intravenous immunoglobulin IVIG Laboratory Measures mitigate outcome Patient receiving recent reported risk severe coronavirus disease shielding subcutaneously Subjective transitioned [DOI] 10.1097/ACI.0000000000000864 PMC 바로가기
Phase II/III trial of hyperimmune anti-COVID-19 intravenous immunoglobulin (C-IVIG) therapy in severe COVID-19 patients: study protocol for a randomized controlled trialArticle Published on 2022-11-082022-11-16 Journal: Trials [Category] SARS, 변종, [키워드] adaptive anti-COVID-19 IVIG antivirals clinical evidence clinical trial collected convalescent convalescent plasma COVID-19 cumulative death Efficacy eligibility criteria evaluate Health hyperimmune immunization immunomodulators intravenous Intravenous immunoglobulin low dose monoclonal antibodies Neutralizing non-specific novel Novel coronavirus outcome Passive passive immunization Patient phase Pneumonia polyclonal polyclonal antibodies Pooled convalescent plasma Potential treatment Randomized Randomized controlled trial receive Recovered COVID-19 patients reported SARS CoV-2 SARS CoV-2. SARS-CoV-2 sealed Secondary outcomes severe COVID-19 severe COVID-19 patient severe COVID-19 patients Standard of care Steroids Study protocol therapeutic option therapy treat Treatment Trial variant variants of concern virus virus particles World Health Organization [DOI] 10.1186/s13063-022-06860-2 PMC 바로가기
An ACE2 decoy can be administered by inhalation and potently targets omicron variants of SARS-CoV-2Article Published on 2022-11-082022-11-15 Journal: EMBO Molecular Medicine [Category] SARS, 변종, 유전자 메커니즘, 진단, [키워드] ACE2 Administered administration ameliorated Angiotensin-converting enzyme angiotensin-converting enzyme 2 antibody betacoronaviruses bind catalytic activity catalytically active Clinical use COVID-19 decoy demonstrated effective entry receptor High dose Host increased survival Infection Inflammation inoculated intravenous intravenously K18-hACE2 mice Loss Lung injury mechanism neutralization potency neutralize omicron Omicron variant persist PROTECT receptor receptor. reduced sACE2 SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants shown substrate target the SARS-CoV-2 therapeutic efficacy therapeutic potential Treatment virus [DOI] 10.15252/emmm.202216109 PMC 바로가기
Randomized, double-blind, placebo-controlled, crossover trial of oral doxycycline for epistaxis in hereditary hemorrhagic telangiectasiaArticle Published on 2022-11-072022-11-16 Journal: Orphanet Journal of Rare Diseases [Category] 유전자 메커니즘, [키워드] analysis Angiogenesis assigned Biomarkers bleeding Blood center double-blind doxycycline Effectiveness ENG Epistaxis Frequency heart failure help hemorrhage Hemorrhagic Hereditary Hereditary hemorrhagic telangiectasia Hereditary hemorrhagic telangiectasia. HHT IL-6 Inflammatory intravenous limitations Liver disease malformation marker mechanism Michael morbidity no significant difference not significantly different observation pathway Patient Placebo placebo-controlled provided Quality of life Randomized controlled trial Randomly RBC recruited Registered Registration secondary significantly higher stroke telangiectasia therapy Toronto Treatment treatment period Trial VEGF [DOI] 10.1186/s13023-022-02539-8 PMC 바로가기
Development of IgA vasculitis with severe glomerulonephritis after COVID-19 vaccination: a case report and literature reviewArticle Published on 2022-11-012022-11-15 Journal: CEN case reports [Category] 진단, [키워드] accompanied Acute kidney injury administration applied Case report COVID-19 COVID-19 pandemic COVID-19 vaccination COVID-19 vaccine Cyclophosphamide development Glomerulonephritis Hematuria IgA IgA Vasculitis IgAV. Immunosuppressive treatment initial injection Intensive intractable intravenous Japanese kidney literature review nephropathy oral steroid Patient performed Pfizer-BioNTech pulse purpura remained renal function reported resolved second dose second vaccination Spread syndrome Treatment Vasculitis [DOI] 10.1007/s13730-022-00695-1 PMC 바로가기
Antibody response after COVID-19 vaccination in intravenous immunoglobulin-treated immune neuropathiesArticle Published on 2022-11-012022-11-15 Journal: European journal of neurology [Category] SARS, 진단, [키워드] Administered administration age Alter analyzed anti-SARS-CoV-2 anti-SARS-CoV-2 antibody anti-SARS-CoV-2 IgG antibodies COVID-19 COVID-19 vaccination COVID-19 vaccine decrease dose enzyme-linked immunosorbent female healthy subjects IgA IgA titer IgG IgG titer IgM immune immunoassay Immunoglobulin impair indicate Interaction intravenous Intravenous immunoglobulin IVIG Microparticle mRNA vaccine observation Patient positive Prevalence reduce remained sera serological response serum serum titer significantly subsequent the antibody response therapeutic vaccination Vaccine vaccine dose vaccine interaction. [DOI] 10.1111/ene.15508 PMC 바로가기
Bamlanivimab Use in a Military Treatment FacilityArticle Published on 2022-10-292022-11-15 Journal: Military Medicine [Category] COVID19(2023년), SARS, 진단, [키워드] acute respiratory syndrome Administered administration Admission analyzed approval approved Arm bamlanivimab Care caused cohort study coronavirus coronavirus disease COVID-19 COVID-19 patient death declined diagnosed Disease progression facility FDA Follow-up Guidance help hospital Hospital admission Hospitalization information initial inpatient admission institutional review board intravenous IRB lack Mild-to-moderate monoclonal antibody Patient patients patients with SARS-CoV-2 placebo group Prevent Primary outcome progression provided receiving replicated reported required retrospective risk risk factor SARS-CoV-2 secondary outcome self-reported symptom severe COVID-19 small sample size Spread statistical significance statistically significant Study design Symptom treated Treatment treatment group virus-neutralizing was obtained were given Wuhan, China [DOI] 10.1093/milmed/usab188 PMC 바로가기
Omicron Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization by Immunoglobulin Preparations Manufactured From Plasma Collected in the United States and EuropeArticle Published on 2022-10-172022-11-15 Journal: The Journal of Infectious Diseases [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome antibody collected coronavirus coronavirus 2 coronavirus disease COVID-19 Donor Europe European Immunoglobulin Infection intravenous Intravenous immunoglobulin less neutralization Neutralizing Neutralizing antibodies new virus omicron pandemic plasma preparation Primary Immunodeficiency Prophylaxis Prophylaxis. proportion raising respiratory SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2 antibody potency the United State union United State vaccination variant virus [DOI] 10.1093/infdis/jiac358 PMC 바로가기
Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected During the 2020 PandemicArticle Published on 2022-10-172022-11-15 Journal: The Journal of Infectious Diseases [Category] COVID19(2023년), SARS, 진단, [키워드] acute respiratory syndrome anti-SARS-CoV-2 convalescent plasma coronavirus coronavirus 2 coronavirus disease correlation COVID-19 cumulative dose first positive immune immunodeficiency Immunoglobulin incidence Increasing intravenous intravenous immune globulin Neutralizing Neutralizing antibodies plasma positive Primary Immunodeficiency Prophylactic Prophylaxis released respiratory SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2 antibody potency secondary immunodeficiency. tested Treatment [DOI] 10.1093/infdis/jiab142 PMC 바로가기
Efficacy of COVID-HIGIV in animal models of SARS-CoV-2 infectionArticle Published on 2022-10-102022-11-15 Journal: Scientific Reports [Category] COVID19(2023년), SARS, 비임상, 진단, [키워드] acute respiratory syndrome animal model anti-SARS-CoV-2 baseline Body weight loss caused China controls convalescent plasma coronavirus COVID-19 COVID-19 vaccines deaths Efficacy evaluated faster hamster hamsters Hospitalization Human Immunoglobulin intravenous Lung inflammation Lung pathology Lungs mice monoclonal antibody mouse model ongoing trial PBS plasma reduced SARS-CoV-2 SARS-COV-2 infection significantly Spread Support therapeutic option treated Treatment Viral load virus was reduced worldwide pandemic [DOI] 10.1038/s41598-022-21223-2 PMC 바로가기